regulatory agencies are super careful wrt testing in vulnerable populations bc of the risk and prior hx of "enhanced RSV disease" (ERD) w early generation vaccines. So a decent body of safety data in adults, followed by toddlers, seropositive infants, etc. is necessary prior to giving it to seronegative infants. Hence the lag in the infant vaccine
I think maternal vaccine would obviously cover the most at risk populations - premies and neonates ages 0-3mo, but there is still disease burden in older infants after passive maternal immunity wanes so it could also become added to routine infant and child vaccination strategy (when i checked MRNA their plan is to ultimately have a 3 in one vaccine to cover respiratory diseases)
I just checked and it looks like they just started phase 1 - so several years behind GSK
yes and this seems to be the largest market opportunity. The adjuvenated vaccine will likely command premium pricing compared to infant vaccine (ala shingrix)
PS: I cannot find a link to the GSK webcast from ID week but hopefully the company will make a replay available
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.